📢 #IBD practices - are you looking to add or optimize the role of #pharmacist on your team? ✅ below for information on what services IBD pharmacists provide and how to justify the addition of one on your team! @IBD_FloMD @MRegueiroMD @IBDJournals

@MondayNightIBD 1/Pregnancy & #IBD -What Every Clinician Should Know🩺🤰 IBD adds unique challenges to pregnancy, but remission & proper management make healthy outcomes the rule not the exception Let’s walk through key updates, meds, monitoring, & delivery pearls🧵👇 #MFM #ObgynTwitter @IBDBen

@PhilFleshnerMD @GKochharMD provided a great endoscopic review including techniques and place in patient care:

@PhilFleshnerMD highlighting surgery related updates, particularly focusing on role and timing of surgery in comparison to biologic treatment.

@DCharabaty @MRegueiroMD @EdBarnesMD @MRegueiroMD making a second appearance to discuss treatment positioning in UC and CD! Several factors to consider here including tx class feature and clinical scenario:

@DCharabaty @MRegueiroMD @EdBarnesMD Dr. Banarjee shared her wonderful work in India, aiming to understand the pathophysiology of #IBD and potential prevention interventions. Lots of variability identified thus far but signs point to value eating right, sleeping well, exercising, and avoiding stress.

ONE WEEK AWAY! #IBD education is coming to Cleveland, Oct 11-12 Join local experts for high-impact sessions on Crohn’s, UC, biologics, APP strategies and so much more. Join: @IBD_FloMD, @tinahamd, @MaiaKayalMD Register Today: https://t.co/KjBZs4hbR9

@DCharabaty @MRegueiroMD @EdBarnesMD reviews #pouchitis: what we currently know, current tx recommendations including antibiotics and biologics, patient perceptions of pouches vary, and how management is changing time.

@DCharabaty @MRegueiroMD discussed post-op CD. Surgery not a cure but LIR!C showed laparoscopic ileocaecal resection is cost-effective tx with similar quality-of-life outcomes to infliximab tx. Post-op surveillance options include non-invasive monitoring (IUS, FCP).

Great overview on pregnancy by @DCharabaty. Take 🏠 point is "healthy mom, healthy baby". Thanks to #PIANO registry, we now have more data about meds in🤰🏽and breastfeeding!

Heath maintenance in #IBD by Dr. Hashash. 🔑points: - encompasses vaccinations and other health screenings like bone scan, smoking cessation, etc. - do not defer or delay treatment for vaccination completion - several checklists are available

AHN #IBD Summit is off to a great start with review of #ASUC management by @MaiaKayalMD! Some ⭐ points: - IFX, dose optimize to >10 mg/kg if low albumin - consult surgeon early - in process of saving lives, not colons - role of JAK use is evolving

#UC approval per Astro: - sx response as soon as 2wk - wk 12: clinical remission 26% vs. 7%; endoscopic improvement 36% vs. 12%; p<0.001 - wk 24: clinical remission (100 mg: 34%, 200 mg: 34% vs. 10%; p<0.001); endoscopic improvement (100 mg: 39%, 200 mg: 44% vs. 12%); p<0.001

#Tremfya (guselkumab) SQ induction is now FDA approved for both #CD and #UC! 🙌🏽 Induction SQ dose: 400 mg (using two 200 mg injections) at weeks 0, 4, 8. Alternatively, infusions can be administered at 200 mg (1 hour each) at weeks 0, 4, 8! #IBD #GITwitter

Our latest takeaways from our live on “Demystifying Biosimilars & Biologics in IBD” tackle common myths & highlight the vital role of #Biologics in #IBD treatment! ▶️Access the full talk & additional resources here: https://t.co/S5yKTpmGaC #Crohns #UlcerativeColitis

Critical to end the @US_FDA history of requiring placebo and long washouts in #IBD clinical trials. The evidence continues to accumulate that these are not necessary (TNF biosims = active comparator, short washouts in practice) and in violation of DoH p32

🚀Dive into the future of IBD care at the 7th Annual AHN IBD Summit happening Saturday, October 4, 2025! 🚀 Explore innovations in endoscopic management, updates on biosimilars, & IBD in pregnancy. Register now at https://t.co/gFrkcmKQ1J! #IBDsummit #AHN #gastroenterology

🔮 Where do you want to take IBD remission in the near future —if cost and access were no barrier? Let’s reimagine the future of remission. Which endpoint would you aim for? 📊 Pick your target: 💬 Cast your vote and comment why! Let’s shape the future of #IBD care—together.

We are proud to host an amazing panel discussion to demystify #Biologics & #Biosimilars in #IBD! Join @ibdtweets 🇺🇸 moderating #HarshadJoshi 🇮🇳, @ashmem 🇺🇸 & #TanyaManohar 🇮🇳 who share how biologics & biosimilars work! Tune in on Sat, 19 Jul live: https://t.co/LFOlDAN6aL

Excited to contribute to this issue to highlight the role of #pharmacists in #GI care!

Interesting study relating to current analysis of #adalimumab (Humira) #biosimilars trends and use in practice. Switches are predominantly payer mandated and 1 in 8 patients are switching back to reference adalimumab, mostly within 30 days of switch. https://t.co/EzeeRIFSGt